CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total revenue	$ 104,672	$ 69,096	$ 301,962	$ 200,266
COST OF REVENUE	53,840	36,775	155,049	110,111
GROSS PROFIT	50,832	32,321	146,913	90,155
Operating expenses:
General and administrative	33,054	21,055	94,773	59,106
Research and development	2,611	446	6,407	2,475
Sales and marketing	11,508	6,900	35,048	21,355
Total operating expenses	47,173	28,401	136,228	82,936
INCOME FROM OPERATIONS	3,659	3,920	10,685	7,219
Interest expense, net	203	1,873	3,333	4,766
Other (income) expense	(35)	(30)	5,124	31
Loss on extinguishment of debt	0	0	1,018	0
Income before taxes	3,491	2,077	1,210	2,422
Income tax expense (benefit)	1,348	54	(500)	135
NET INCOME	2,143	2,023	1,710	2,287
Deemed dividends on preferred stock and amortization of beneficial conversion feature	0	0	0	5,627
Gain on redemption of preferred stock	0	0	0	(9,075)
NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ 2,143	$ 2,023	$ 1,710	$ 5,735
INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic (in dollars per share)	$ 0.02	$ 0.02	$ 0.02	$ 0.07
Diluted (in dollars per share)	$ 0.02	$ 0.02	$ 0.02	$ 0.06
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	103,899	87,253	99,149	87,381
Diluted (in shares)	107,880	90,899	102,766	89,925
Clinical Services
Total revenue	$ 92,565	$ 59,449	$ 267,757	$ 175,960
GROSS PROFIT	45,039	27,940	131,200	81,374
Pharma Services
Total revenue	12,107	9,647	34,205	24,306
GROSS PROFIT	$ 5,793	$ 4,381	$ 15,713	$ 8,781